IP Library Granted Patent US 9,840,721
Granted Patent B2
US 9,840,721 · App. 15/051,907 · Granted Dec 12, 2017

Recombinant retrovirus pseudotyped with E2 alphavirus glycoprotein

Inventors: Pin Wang (Arcadia, CA); Lili Yang (Arcadia, CA); David Baltimore (Pasadena, CA)
Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
C12N15/86A61K31/70A61K35/76A61K38/177A61K38/178A61K38/1774A61K38/1793A61K38/191A61K38/193A61K38/20A61K38/204A61K38/2013A61K38/2026A61K38/2046A61K38/2086A61K39/21C07K14/005C12N7/00A61K2039/5256C12N2740/13043C12N2740/13045C12N2740/15041C12N2740/15043C12N2740/15045C12N2770/36122C12N2770/36134C12N2810/609C12N2810/855
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,840,721
App. No.
15/051,907
Granted
Dec 12, 2017
Kind
B2
Abstract

Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.

Claims (7)

1. A recombinant replication deficient lentivirus pseudotyped with a modified alphavirus E2 glycoprotein that more efficiently transduces dendritic cells compared to other cell types; wherein the lentivirus comprises an exogenous polynucleotide of interest.

2. The recombinant lentivirus of claim 1 , wherein the recombinant lentivirus comprises an inactivated or self-inactivating 3′ LTR.

3. The recombinant lentivirus of claim 1 further pseudotyped with an E1 alphavirus glycoprotein.

4. The recombinant lentivirus of claim 1 wherein the lentivirus is a human immunodeficiency virus (HIV), murine stem cell virus (MSCV), or murine leukemia virus (MLV).

5. The recombinant lentivirus of claim 1 wherein the polynucleotide of interest encodes a protein selected from the group consisting of GM-CSF, IL-2, IL-4, IL-6, IL-7, IL-15, IL-21, IL-23, TNFα, B7.1, B7.2, 4-1BB, CD40 ligand (CD40L) and drug-inducible CD40 (iCD40).

6. The recombinant lentivirus of claim 1 wherein the alphavirus E2 glycoprotein is a Sindbis virus E2 glycoprotein.

7. The recombinant lentivirus of claim 6 wherein the lentivirus is a human immunodeficiency virus (HIV), murine stem cell virus (MSCV), or murine leukemia virus (MLV).

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 21, 2016
From: CALIFORNIA INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038964/0195 →
Continuity (7)
Continuation 14532371 · Nov 4, 2014
Division 13887908 · May 6, 2013
Continuation 12688689 · Jan 15, 2010
Continuation 11781865 · Jul 23, 2007
Provisional Application 60920260 · Mar 27, 2007
Provisional Application 60832497 · Jul 21, 2006
Related Publication 20160340692A1 · Nov 24, 2016